Top Ten most popular articles on Pharmafile.com this week
pharmafile | August 25, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â life sciences, medicine, pharma, pharmaceutical, top tenÂ
As much as it might try, the pharmaceutical industry just isn’t able to keep the drug pricing debate out of the headlines. Two of our top stories were regarding companies raising, or being accused of raising, prices to eye-catching levels. As well as this, there were some major moves by Novartis into the digital sphere that caused waves.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Collaboration between Lilly and CRUK progresses to clinical trials
Cancer Research UK announced that its collaboration with Eli Lilly for the treatment of advanced solid tumours will progress to the clinic, with trials taking place across four centres in the UK.
9. Antibacterial power of mother’s milk revealed
Researchers from Vanderbilt University have discovered a previously unknown ability of mother’s milk to protect new-borns from infections.
8. Novartis names new Chief Digital Officer
Two studies published in Nature may be able to explain some of the reasons for this and potentially offer a way to boost the success rates of the PD-L1 inhibitors.
7. Roche receives FDA Priority Review for drug with potted history
Rocherevealed that it had received Priority Review and an acceptance of a BLA for its haemophilia A drug, emicizumab, but the story of the drug isn’t quite as simple as the acceptance.
6. Hikma risks a stratospheric 430% price increase on product
Hikma, a generic drugmaker, was revealed as planning an increase of 430% on the price of its medicine for diarrhoea – a dangerous move with the pricing debate still swirling.
5. Janssen opposes use of its drug in state execution
Janssen has spoken out against plans to use an anaesthetic drug it invented over 50 years ago to execute prisoners, adding its voice to many others in the pharmaceutical industry who have taken similar stances in recent years.
4. Novartis gets EU nod for potential blockbuster breast cancer drug
Novartis has released that it has received marketing approval from the European Commission for its drug, Kisqali, to used in the treatment of breast cancer.
3. Scientists discover ‘Achilles’ heel’ of oesophageal cancer
Researchers from The Institute of Cancer Research have potentially found a new use for Imbruvica, after discovering a weakness in certain types of oesophageal cancer.
2. Novartis launches first large-scale smartphone-based study in multiple sclerosis
Novartis launched what it claimed is the first large-scale mobile research study which will gather data on multiple sclerosis from patients via their smartphones, removing the need for them to visit a medical professional at the clinic.
1. US Congressmen accuse Teva of price hikes over 1,000%
A pair of US Congressmen fired allegations at Israeli drugmaker Teva, accusing the firm of hiking the price of its multiple sclerosis treatment Copaxone (glatiramer acetate) by more than 1,000% since 1996.
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
